Diagnosis, management and impact on patients' lives of cancer-related neuropathic pain (CRNP): A European survey
Menée par enquête dans 13 pays européens auprès de 24 733 participants atteints d'un cancer (549 répondants), cette étude analyse l'effet, sur leurs activités de la vie quotidienne, d'une douleur neuropathique liée à la maladie et analyse la prise en charge de cette douleur
Objective : This study assessed the impact of cancer-related neuropathic pain (CRNP) on patients and the importance of the patient–healthcare professional (HCP) relationship in diagnosis and management. Methods : A quantitative online survey was conducted involving adult patients from 13 European countries who had been diagnosed with treatable cancer and experienced symptoms of peripheral neuropathy. Results : Of 24,733 screened respondents, 549 eligible persons met the inclusion criteria and completed the questionnaire. Among individuals still experiencing pain, 75% rated it as ‘severe’ or ‘moderate’. In addition, 61% reported a negative impact on day-to-day activities, and 30% said they had stopped working as a result. A third of respondents had received no diagnosis of CRNP despite reporting painful symptoms to an HCP. HCPs spending enough time discussing pain and understanding the impact on patients' lives were each associated with an increased likelihood of a formal CRNP diagnosis. Compared with individuals currently in active cancer treatment, cancer survivors were less likely to have a diagnosis of CRNP or regular pain conversations with HCPs. Conclusion : CRNP remains under-recognised despite its substantial impact on patients' lives. Clinical practice may be improved by strengthening patient–HCP relationships around pain discussions and increasing the focus on pain management among cancer survivors.